Conventional therapies for raised intracranial pressure (ICP) frequently are not effective. We report a patient with raised ICP following a large hemispheric stroke. After conventional therapies had failed, indomethacin was repeatedly administered. After bolus infusion (50 mg), the ICP fell by a mean of 8.1 mm Hg, and the mean arterial blood pressure increased by a mean of 7.1 mm Hg, leading to a mean increase in the cerebral perfusion pressure by 15.3 mm Hg. After 1 h, the ICP had returned to baseline values after most infusions. Continuous infusion of indomethacin was not effective. We conclude that indomethacin may reduce elevated ICP over a short time in patients with ischemic brain edema even after conventional therapy has failed.

Keywords:
Indomethacin, Brain edema, Intracranial pressure, Stroke
1.
Hacke W, Schwab S, Horn M, Spranger M, De Georgia M, v. Kummer R: Malignant middle cerebral artery territory infarction: Clinical course and prognostic signs. Arch Neurol 1996;53:309–315.
2.
Biestro AA, Alberti RA, Soca AE, Cancela M, Puppo CB, Borovich B: Use of indomethacin in brain-injured patients with cerebral perfusion pressure impairment: Preliminary report. J Neurosurg 1995;83:627–630.
3.
Dahl B, Bergholt B, Cold GE, Astrup J, Mosdal B, Jensen K, Kjaersgaard JO: CO2 and indomethacin vasoreactivity in patients with head injury. Acta Neurochir 1996;138:265–273.
4.
Jensen K, Öhrström J, Cold GE, Astrup J: The effects of indomethacin on intracranial pressure, cerebral blood flow and cerebral metabolism in patients with severe head injury and intracranial hypertension. Acta Neurochir 1991;108:116–121.
5.
Coyle MG, Oh W, Stonestreet BS: Effects of indomethacin on brain blood flow and cerebral metabolism in hypoxic newborn piglets. J Am Physiol 1993;H141–H149.
6.
Nilsson F, Björkman S, Rosén I, Messeter K, Nordström CH: Cerebral vasoconstriction by indomethacin in intracranial hypertension. Anesthesiology 1995;83:1283–1292.
7.
Armstead WM, Mirro R, Busija DW, Leffler CW: Opioids and the prostanoid system in the control of cerebral blood flow in hypotensive piglets. J Cereb Blood Flow Metab 1991;11:380–387.
8.
Leffler CW, Busija DW; Beasley DG, Fletcher AM: Maintenance of cerebral circulation during hemorrhagic hypotension in newborn pigs: Role of prostanoids. Circ Res 1986;59:562–567.
9.
Markus HS, Vallance P, Brown MM: Differential effect of three cyclooxygenase inhibitors on human cerebral blood flow velocity and carbon dioxide reactivity. Stroke 1994;25:1760–1764.
10.
Wang Q, Paulson OB, Lassen NA: Indomethacin abolishes cerebral blood flow increase in response to azetazolamide-induced extracellular acidosis: A mechanism for its effect on hypercapnia. J Cereb Blood Flow Metab 1993;13:724–727.
11.
Yen MH, Lee SH: Effect of cyclooxygenase and lipoxygenase inhibitors on cerebral oedema induced by freezing lesions in rats. Eur J Pharmacol 1987;133:369–373.
12.
Muizelaar JP, Marmarou A, Ward JD, Kontos HA, Choi SC, Becker DP: Adverse effects of prolonged hyperventilation in patients with severe head injury: A randomized clinical trial. J Neurosurg 1991;75:731–739.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.